DEXCOM, INC. (DXCM): what the price assumes

In the published model solve dated 2026-Q2, anchored at $91.00, DEXCOM, INC. (DXCM) is priced for today's economics sustained for ~5.3 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/DXCM

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 6: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 10.1% cost of capital; growth searched up to the 32% self-funding ceiling.

How unusual the bet is: n/a

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.9%); the inversion above states its own rate.

Per-Model Detail (n=18)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Most of the revenue never touches a Dexcom invoice to a patient: roughly 85% moves through distributors, with the direct remainder booked at net realizable value "using estimates of claim denials and historical reimbursement experience".
• The price embeds a long runway rather than a high rate: about 33 times company-wide operating profit, which needs growth near the fastest pace the business could fund from its own cash held for roughly eight years, a persistence only about 27% of comparable fast growers managed.
• Second-quarter results are due July 30, and the newest clearances widen who can buy rather than what they pay: Stelo cleared for pediatric use in June, the 15-day G7 authorized in Canada in July.

Bull Case

Revenue grew 15.6% in 2025. Earnings grew 45.1%. That gap between the two is the whole bull argument in miniature, because it is what operating leverage looks like when it finally arrives: the cost of putting one more sensor on one more arm falls faster than the price does, and the trailing operating margin now sits near 18.4%.

The mechanism behind it is unglamorous and durable. The 10-K describes revenue coming from "the sale of disposable sensors and our reusable transmitter and receiver", which is a consumables business wearing a device company's name. The hardware is a gate; the sensors are the annuity behind it. A patient who starts on the system in one quarter shows up in every quarter after it, and the incremental cost of serving that patient falls as manufacturing scales, which is why profit can grow at three times the pace of revenue without anything unusual happening.

The balance sheet lets that compound without asking holders for anything. Cash and investments run about 2.68 billion dollars against roughly 1.30 billion dollars of borrowings on a funded-debt basis, so the company is a net creditor rather than a net borrower. Interest coverage sits above 60, which is what happens when the borrowings are convertible notes carrying token cash coupons. The share count has also drifted down about 2.1% a year over the four years to March 2026, which is not aggressive, but it is the opposite of what a growth company burning through capital would show.

Set against the diabetes-device cohort, Dexcom is the one converting scale into profit. TNDM, selling pumps into the same patient population, runs a negative operating margin near 8% on revenue of 1.03 billion dollars growing 4.5%. PODD grows faster, 31.9%, but on revenue of 2.90 billion dollars and a 17.5% operating margin, which is essentially the same profitability Dexcom achieves on a base close to twice the size. Growing quickly is common in this category. Growing quickly while earning a real margin on almost five billion dollars of revenue is not.

The forward-looking methods reach today's price without straining, and it is worth being precise about how. The cash-flow approach that gets closest does so by assuming the multiple a buyer pays for the business in year six is the same one buyers pay today, which is an assumption about market conditions rather than about sensors. Strip that assumption out and the case still rests on something concrete: a consumable sold to a chronic condition, with the regulatory perimeter widening rather than narrowing.

Bear Case

Start with a detail in the capital structure that most summaries skip. When the 2028 convertible notes were placed, the company bought capped calls to blunt the dilution, and those capped calls carry an initial cap price of 212.62 dollars a share, "which represents a premium of 80 % over the closing" price at the time. The shares change hands at $71.54. The cash cost of that debt is close to nothing, which is why coverage looks impregnable, but cheap convertible paper is never actually cheap: the price of it is a claim on the equity, and the terms of that claim were set against a very different share price.

That matters because of what today's price is underwriting. At roughly 33 times company-wide operating profit, the shares require growth near the fastest pace the business could fund from its own cash, held for about eight years. Only about 27% of comparable fast growers sustained that pace that long. And the requirement is not robust to small changes in what a buyer demands: add a single percentage point to the required return and the implied runway shortens by roughly two years. If the runway turns out to be five years rather than eight, the multiple supporting the price does not adjust gently, it compresses toward what the backward-looking methods already say.

Those backward-looking methods are worth understanding rather than dismissing. The earnings-power lens prices this company off a five-year average operating profit near 0.60 billion dollars, against about 0.844 billion earned on a trailing basis. The average looks punitive, and in a sense it is. It is also the point: most of this company's profit is recent. The price is paying both for the recent part to be the new baseline and for it to keep compounding on top, and those are two separate bets stacked on one another.

The channel is where a disappointment would actually arrive. Roughly 85% of revenue moves through distributors, which means list price and realized price are different numbers separated by negotiation. The filing spells out the machinery: chargebacks to participating entities equal to "the difference between their acquisition cost and the lower negotiated price", and direct receivables carried net of estimated claim denials. In a category where the sharpest competitive weapon is the price offered to payors and pharmacy benefit managers, that arithmetic is where margin quietly leaves the building, and it does so without a single unit of volume being lost.

None of this says the category is slowing. PODD is growing 31.9%, faster than Dexcom, in an adjacent product on the same patients. The bear case is not that continuous glucose monitoring stops mattering. It is that eight years is a long time to hold a near-ceiling growth rate in a market whose largest customers are institutions whose entire job is to negotiate the price down.

Valuation

Today's price works out to roughly 33 times company-wide operating profit. Run that backward and it does not ask for a heroic growth rate so much as a heroic duration: growth near 25% a year, about the fastest pace the business could fund from its own cash, sustained for something like eight years. Of the fast growers this can be compared against, only about 27% held that pace that long. The bet is on persistence.

The methods sort themselves cleanly. The forward-growth approaches reach the price, and the peer-multiple family sits just beneath it, with the price about 21% above where peer multiples land. The earnings-power methods finish well short, with the price around twice what that family supports, and the asset-value approaches fall short of it too. That is the signature of a durability premium: only the lens that credits future growth defends what is being paid, and the static lenses structurally cannot frame an eight-year runway.

The earnings-power reading deserves an explanation rather than a dismissal, because the reason it sits low is instructive. It capitalizes a five-year average operating profit near 0.60 billion dollars, against roughly 0.844 billion on a trailing basis. A five-year average is a harsh lens for a business that only recently reached scale. It also quantifies exactly how recent the profitability is, which is precisely the variable the eight-year assumption depends on.

Cohort position is mid-pack on profitability and behind on pace. PODD earns a 17.5% operating margin on revenue of 2.90 billion dollars growing 31.9%, with a 71.0% gross margin. TNDM is smaller still at 1.03 billion dollars and loss-making at the operating line. Against those, an 18.4% trailing operating margin on a revenue base near 4.82 billion dollars is the strongest combination of size and profitability in the group, and the weakest growth rate among the profitable members of it.

Solvency takes financing risk off the table entirely. Cash and investments of about 2.68 billion dollars sit against roughly 1.30 billion dollars of borrowings on a funded-debt basis, leaving the company a net creditor, and interest coverage above 60 reflects convertible notes whose cash coupons are nominal. What that structure removes is the possibility of being forced into a bad decision by a lender. What it does not touch is duration, which is the only variable the price actually turns on.

Catalysts

Second-quarter results are scheduled for July 30, 2026 at 4:30 p.m. Eastern. The comparison they land against is a 2025 in which revenue reached $4.66 billion, up 15.6%, and earnings rose 45.1%.

The regulatory run over the past two months has been unusually dense, and each item widens the buyer base rather than the price. On June 12 the FDA cleared Stelo as the first over-the-counter continuous glucose monitor authorized for children. On June 23 the company laid out further biosensing milestones including that pediatric clearance. On July 13 the 15-day version of G7 received Health Canada authorization. On July 22 the company was named the first participant in the FDA's TEMPO digital health devices pilot.

The thing to watch through all of it is mix. Over-the-counter and pediatric channels bring in users who were previously outside the prescription pathway, but they arrive through the same distributor structure that carries roughly 85% of revenue, where price is negotiated rather than posted. Unit growth that shows up alongside a stable margin would confirm the operating leverage of the last two years. Unit growth that arrives with margin slipping would say the new users are being bought rather than won.

Peer Cohorts (Per Segment, With Filing Citations)

DexCom (single reportable segment - CGM disposable sensors and Reusable Hardware) (reported)

• PODD (INSULET CORPORATION)
• FY2025 10-K: …funds with a limited number of financial institutions that have a high investment grade credit rating. See Notes 4 and 5 for customer concentration. Supply Risk- The Company uses different types of semiconductor chips, which are sourced from external suppliers, in the manufacturing of its products. While the Company…
• FY2025 10-K: Reporting . Increasingly, regulators, customers, investors, employees, and other stakeholders are focusing on environmental, social, and governance matters and related disclosures. The collection, measurement, and reporting of environmental data is subject to evolving reporting standards, including California's…
• TNDM (Tandem Diabetes Care, Inc.)
• FY2025 10-K: …or approval for any such updates; • changes in reimbursement rates or policies relating to insulin pumps or similar products or technologies by third-party payors; • competitive pricing and attrition rates of consumers who cease using our products; • our inability to enter into contracts with third-party payors on a…
• FY2025 10-K: …a new pump. These enhancements generally include new developments in our AID technology, CGM integrations and mobile app features. For more than a decade we have offered our customers, their caregivers and healthcare providers a data management application to provide a fast, easy and visual way to display diabetes…
• IRTC (iRhythm Holdings, Inc.)
• FY2025 10-K: …well as the wireless gateway used in conjunction with Zio AT. As PCBAs are used in a wearable Zio monitor, Zio XT, or Zio AT, a portion of the cost of the PCBA is recorded as a cost of revenue. We base our length of time estimates for charging a portion of the PCBAs cost through several considerations, including…
• FY2025 10-K: …regarding matters that are inherently uncertain. Our most critical accounting estimates include: • Revenue recognition; • Provision for credit losses and contractual allowances; • PCBA valuation; • Stock-based compensation; • Lease impairment; and • Contingent consideration. Revenue Recognition We have developed…
• MMSI (MERIT MEDICAL SYSTEMS INC)
• FY2025 10-K: …to jurisdiction, and are subject to evolving (and at times inconsistent) governmental interpretation, compliance with these laws and regulations may require significant additional cost expenditures or changes in products or business that increase competition or reduce revenue. Noncompliance with such laws or…
• FY2025 10-K: …of our portfolio of spine products, representing approximately $ 22.6 million and $ 22.4 million in revenue, respectively, within the OEM product category to provide comparability between the reported periods. ​ ​ ​ ​ 3. ACQUISITIONS AND OTHER STRATEGIC TRANSACTIONS 2025 Acquisitions On November 3, 2025, we entered…
• BSX (BOSTON SCIENTIFIC CORP)
• FY2025 10-K: …devices. In accordance with FASB ASC Topic 280, Segment Reporting, we identified our reportable segments based on the nature of our products, production processes, type of customer, selling and distribution methods and regulatory environment, as well as the economic characteristics of each of our operating segments.…
• FY2025 10-K: …related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts…
• PEN (Penumbra, Inc)
• FY2025 10-K: …the goods or services are highly interdependent. Revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly…
• FY2025 10-K: …and as such the significant segment expenses regularly provided to the CODM are those presented on the consolidated statements of operations. These significant segment expense include cost of revenue, research and development, and sales, general and administrative expenses. Other segment items that are presented on…
• GMED (GLOBUS MEDICAL, INC.)
• FY2025 10-K: …price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligation(s). Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange…
• FY2025 10-K: …used in an expansive range of spine, orthopedic trauma, hip, knee and extremity procedures. The majority of our Musculoskeletal Solutions contracts have a single performance obligation and revenue is recognized at a point in time. For our IONM services, revenue is recognized in the period the service is performed for…
• EW (EDWARDS LIFESCIENCES CORPORATION)
• FY2025 10-K: …Other Information" in the Proxy Statement is incorporated herein by reference. Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters The information contained under the headings "Security Ownership of Certain Beneficial Owners" "Stock Ownership of Directors and…
• FY2025 10-K: …in certain foreign subsidiaries (designated as net investment hedges) and (3) foreign currency denominated assets or liabilities (designated as fair value hedges). The Company also uses foreign currency forward exchange contracts that are not designated as hedging instruments to offset the transaction gains and…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.